| Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions (NCT05476978) | Huazhong University of Science and Technology | 2022-07-01 |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors (NCT05040360) | SWOG Cancer Research Network | 2022-05-05 |
| Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy (NCT05171517) | Peking Union Medical College Hospital | 2022-01-01 |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) (NCT04924075) | Merck Sharp & Dohme LLC | 2021-08-12 |
| Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer (NCT04505553) | University of Washington | 2021-06-01 |
| Neoadjuvant PRRT With Y-90-DOTATOC in pNET (NCT05568017) | European Institute of Oncology | 2020-09-15 |
| Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (NCT03947762) | Ipsen | 2019-07-03 |
| Pancreatic Fistula After Minimally Invasive Enucleation (NCT06557408) | Fudan University | 2019-07-01 |
| Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction (NCT06024343) | Fudan University | 2019-07-01 |
| Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region (NCT04134832) | University Hospital, Strasbourg, France | 2019-06-27 |
| CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms (NCT03967951) | Francesco De Cobelli | 2019-03-23 |
| Biomarker Study of Pancreatic Neuroendocrine Tumours (NCT03741517) | Uppsala University | 2019-01-30 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors (NCT03600233) | TaiRx, Inc. | 2018-12-15 |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms (NCT03435770) | Singapore General Hospital | 2018-03-01 |
| Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions. (NCT03417843) | HaEmek Medical Center, Israel | 2018-02-01 |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study (NCT03147768) | Laser Tissue Welding, Inc. | 2018-01-01 |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors (NCT03074513) | M.D. Anderson Cancer Center | 2017-03-03 |
| A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor (NCT03204019) | Chinese Academy of Medical Sciences | 2016-10-01 |
| Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival (NCT02624154) | First Affiliated Hospital, Sun Yat-Sen University | 2015-12-01 |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 (NCT02355535) | Vanquish Oncology, Inc. | 2015-02-01 |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (NCT01466036) | Dana-Farber Cancer Institute | 2012-07-01 |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (NCT01024387) | Dana-Farber Cancer Institute | 2010-03-01 |
| Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (NCT00970970) | University Medical Center Groningen | 2009-09-01 |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00942682) | Dana-Farber Cancer Institute | 2009-07-01 |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00804336) | Dana-Farber Cancer Institute | 2008-10-01 |
| RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT00576680) | Dana-Farber Cancer Institute | 2008-05-01 |
| A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (NCT00428220) | Pfizer | 2007-07-01 |